Redmile Group LLC Has $147.49 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Redmile Group LLC lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 20.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 810,245 shares of the company's stock after selling 210,833 shares during the period. Krystal Biotech makes up approximately 8.7% of Redmile Group LLC's holdings, making the stock its largest position. Redmile Group LLC owned 2.82% of Krystal Biotech worth $147,489,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in KRYS. Dimensional Fund Advisors LP grew its position in Krystal Biotech by 1.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company's stock worth $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Hood River Capital Management LLC grew its position in Krystal Biotech by 5.1% during the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company's stock worth $95,694,000 after buying an additional 25,507 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Krystal Biotech by 9.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company's stock valued at $43,727,000 after acquiring an additional 19,777 shares during the period. Bank of New York Mellon Corp raised its holdings in Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company's stock valued at $35,583,000 after acquiring an additional 103,928 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Krystal Biotech by 11.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company's stock worth $32,402,000 after acquiring an additional 18,021 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KRYS. HC Wainwright restated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Citigroup lifted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Stifel Nicolaus increased their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Finally, Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Krystal Biotech currently has an average rating of "Buy" and a consensus price target of $202.29.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded down $7.86 during mid-day trading on Thursday, hitting $179.76. 288,402 shares of the stock were exchanged, compared to its average volume of 323,147. Krystal Biotech, Inc. has a twelve month low of $100.98 and a twelve month high of $219.34. The stock's fifty day simple moving average is $181.10 and its two-hundred day simple moving average is $184.26. The company has a market cap of $5.17 billion, a P/E ratio of 101.56 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business's revenue was up 879.9% on a year-over-year basis. During the same period last year, the firm posted ($0.67) EPS. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).